Document is current
Any future updates will be listed below
-
Authors
Fick, Kendra https://orcid.org/0000-0002-6973-434X
Kerns, Nicholas
Zhao, Yang https://orcid.org/0000-0002-9450-3754
Tiamiyu, Zainab
Poschel, Dakota
Czabala, Patrick https://orcid.org/0000-0002-2365-3181
Yang, Dafeng
Tang, Yi https://orcid.org/0009-0009-1019-1174
Xie, Jin
Fesenkova, Valentyna
Pacholczyk, Rafal
Shi, Huidong https://orcid.org/0000-0003-1137-3390
Liu, Kebin https://orcid.org/0000-0003-1965-7240
Redd, Priscilla S https://orcid.org/0009-0004-3231-1564
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05703971 at ClinicalTrials.govnct05062980 at ClinicalTrials.govDocuments that mention this clinical trial
Lipid nanoparticle-delivered IFNα2 activates Cxcl9 to increase T cell tumor recruitment to suppress lung metastasis
https://doi.org/10.1136/jitc-2024-011415
nct04486833 at ClinicalTrials.govDocuments that mention this clinical trial
Lipid nanoparticle-delivered IFNα2 activates Cxcl9 to increase T cell tumor recruitment to suppress lung metastasis
https://doi.org/10.1136/jitc-2024-011415
Documents that mention this clinical trial
Lipid nanoparticle-delivered IFNα2 activates Cxcl9 to increase T cell tumor recruitment to suppress lung metastasis
https://doi.org/10.1136/jitc-2024-011415
ACCLAIM-1 dose escalation: Determination of quaratusugene ozeplasmid and osimertinib recommended phase 2 dose (RP2D).
https://doi.org/10.1200/jco.2023.41.16_suppl.e15081
-
Funding
Funding for this research was provided by:
US Department of Veterans Affairs (I01CX001364)
National Cancer Institute (R01CA264983)
National Cancer Institute (R01CA278852)
National Cancer Institute (R43 CA250780)
- License Information
